Related Experiment Video
Updated: May 6, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Update on evidence for treatment with ranolazine in stable angina
Federico Carbone1, Fabrizio Montecucco, François Mach
1Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Switzerland; fedric8@gmail.com.
Abstract:
Chronic angina represents a major burden for public health systems because of its poor prognosis and its high treatment costs. Ranolazine is an emerging drug recently approved for the treatment of this disease. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. Moreover, this particular mechanism of action also confers on ranolazine a potential antiarrhythmic effect. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.
Insights
Ranolazine, a new drug for chronic angina, works by inhibiting the late sodium current. This mechanism improves heart function and may also prevent arrhythmias, offering new therapeutic options.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Chronic angina presents a significant public health challenge due to poor prognosis and high treatment costs.
- Ranolazine is a recently approved medication for managing chronic angina.
Purpose of the Study:
- To review current evidence on ranolazine for chronic angina.
- To discuss the therapeutic potential of ranolazine based on recent research.
Main Methods:
- Literature review of clinical and experimental studies on ranolazine.
- Analysis of ranolazine's molecular mechanism of action.
Main Results:
- Ranolazine's primary mechanism involves inhibiting the late sodium current (late Na+ current) during cardiac action potentials.
- This inhibition may improve myocardial oxygen consumption, diastolic function, and coronary blood flow.
- The mechanism also suggests potential antiarrhythmic properties for ranolazine.
Conclusions:
- Ranolazine demonstrates promising therapeutic effects in chronic angina.
- Its unique mechanism offers potential benefits beyond symptom relief, including antiarrhythmic effects.
- Further research is ongoing to fully elucidate ranolazine's role in cardiovascular treatment.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management
Angina V: Nursing Management
Acute Coronary Syndrome III: Diagnostic Studies
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Angina III: Clinical Manifestations and Assessment